December 2, 2008

DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product

LANSING, Mich. (Dec. 2, 2008) — DuPont Applied BioSciences has turned to MBI (Michigan Biotechnology Institute) to join the DuPont team in evaluating the commercial viability of an important bio-based product line. MBI International is a leader in bridging the gap between research and commercialization through collaborative de-risking of bio-based technologies. MBI’s unique “Collaborative De-Risking” process systematically addresses technological uncertainties, which impede new technologies from getting to market.

“We are very excited that DuPont Applied BioSciences has chosen MBI as a partner to help de-risk this important new product line,” stated Dr. Bobby Bringi, recently appointed President of MBI International. “We had the opportunity to work with DuPont Applied BioSciences on an initial phase of this project, and are proud that they have chosen to extend this partnership with MBI.”

MBI International fits a unique niche in the marketplace. Virtually all bio-based technology developments that come from the lab need to go through a process development and scale-up stage to determine commercial viability. Once the uncertainties or risks associated with early technological developments are mitigated via de-risking, a company like DuPont
Applied BioSciences is better positioned to make product-related investments. MBI has built a multi-disciplinary team of scientists and engineers, as well as the required pilot-plant facilities, to work collaboratively with industry partners to help address the risks associated with bringing bio-based technologies to market.
MBI also provides connectivity with both Michigan State University and the greater university research community to help
solve complex problems.

“DuPont Applied BioSciences is pleased to continue our collaboration with MBI on this important new product line,” said 
Scott Cunningham, Business Development Manager – DuPont Applied BioSciences. “MBI’s well rounded expertise,
operational flexibility and excellent facilities allowed us to successfully complete Phase I of the project. We are confident
that MBI will help us to evaluate the critical path of this technology and identify opportunities and threats to scale-up and
commercialization.”

”
DuPont is a world leading market-driven, science-based products company, so we are pleased they have chosen to
continue working with our team,” Bringi said. “De-risking high-technology developments is like building a bridge to the
market. It requires experienced partners to work in collaboration with one another at each stage in the process from the
lab through scale-up and then to the market. From our point of view, this relationship helps validate the strategic position
we have chosen for MBI.”

About MBI

MBI (Michigan Biotechnology Institute) is both a premier multidisciplinary center sought out by industry partners for unique derisking capabilities—and a mission-inspired 501(c)(3) not-for-profit that collaboratively accelerates the commercialization of bio-based technologies. MBI is known for pioneering derisking, a process that quickly and cost-effectively fails flawed technologies while accelerating viable ones through a stage-gated innovation process. Lansing, Michigan-based MBI engages with universities, research institutions and corporations to develop sustainable fuels, chemicals, food and feed. Collaborators have included DuPont, Genomatica and Novozymes. MBI has also worked with Michigan State University and Cargill to develop PLA, the first biodegradable polymer in global use. Technologies developed at MBI are recognized and trusted worldwide. Learn more at www.www.mbi.org.